Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Diagnosis & Disease Information
Case Study: Ethics and Mental Illness in Pregnancy
A woman is evaluated by psychiatry on postpartum day 2 after staff noticed her talking to the mirror in her room and not showing affection to her newborn child. Case shows ethical decisions made when managing mental illness during pregnancy.
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Anhedonia Linked to Negative, Positive Symptoms in Schizophrenia
Three clusters detected corresponding to positive symptoms, negative symptoms and work functioning, and functional domains.
Response to Schizophrenia Treatment Varies Based on Genes
Investigators searched PubMed, Cochrane Library, Medline, Embase, CNKI, Weipu, and Wanfang databases for eligible studies through March 2022.
Genetics May Affect Pregnancy Risk Factors for Offspring Neurodevelopmental Conditions
Genetic liability to ADHD, schizophrenia linked to pregnancy-related factors thought to be associated with these conditions.
Can Machine Learning Better Stratify Patients With Early Psychosis?
To better identify and categorize symptoms, researchers developed a machine learning model to “redraw boundaries” within early psychosis.
Bipolar Disorder and Schizophrenia Show Similar Response Inhibition
Researchers sought to find mechanisms of impaired impulsivity control in patients with BD responding to emotion and compare them to patients with schizophrenia.
Continuous Theta Burst Stimulation Treats Auditory Hallucinations in Schizophrenia
For this study, patients with schizophrenia with auditory verbal hallucinations who had inadequate response to at least 1 antipsychotic drug were recruited.
Age- and Gender-Based Trends in Schizophrenia Onset
Investigators evaluated data collected for a population-based study of nearly 1.5 million adults that was conducted at seven sites across Australia.
- Loading...
Loading...
Next post in Schizophrenia Information Center
Loading... 
Loading...